Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | SMO | Q99835 | 5/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15243536 | 0.79 | NOS3 (0.45) | SMOCYP2A6KDM4ENPC1ALDH1A1 | |
| SCHEMBL31501775 | 0.76 | NOS3 (0.38) | CRHR1CYP2A6KDM4ENPC1ALDH1A1 | |
| SCHEMBL27041968 | 0.76 | NOS3 (0.38) | CRHR1CYP2A6KDM4ENPC1ALDH1A1 | |
| SCHEMBL19480729 | 0.76 | HSP90AA1 (0.32) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL18654664 | 0.71 | MAPK13 (0.42) | AGBL2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31078141 | 0.70 | PDE1B (0.51) | NPC1 | |
| SCHEMBL30759891 | 0.69 | ALDH1A1 (0.45) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL27042004 | 0.69 | ALDH1A1 (0.45) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL2083869 | 0.69 | — | — | |
| SCHEMBL16493300 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | HCRTR2, HCRTR1, CNR2 | AGBL2 3513/4885CRHR1 6/4885GABRG2 298/4885 |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | HCRTR2, HCRTR1, CNR1 | AGBL2 3042/4885CRHR1 4/4885GABRG2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.